Supported through an independent educational grant from AstraZeneca.
This educational initiative is targeted to hematologists/oncologists, oncology specialists, pharmacists, nurse practitioners, nurses, and other members of the oncology care team who treat patients with chronic lymphocytic leukemia (CLL).
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education Credit for learning and change.
This application-based activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007101-0000-23-004-H01-P).
This activity is designated for 1.0 contact hour.
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Sandra E. Kurtin, PhD, ANP-C, AOCN–has disclosed that she is an advisor or consultant to Abbvie, Amgen, AstraZeneca, BMS, GSK, and lncyte.
Lauren Willis, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
Jennifer A. Woyach, MD–has disclosed that she is a consultant for Abbvie, AstraZeneca, Beigene, Genetech, Janssen, Loxo, Pharmacyclics, and Newave. She receives grant/research support from Janssen, Karyopharm, Morphosys, Pharmacyclics, and Schrodinger.
Katherine Lee, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Susan Gitzinger, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity